IN
Therapeutic Areas
Navire Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SHP2 Inhibitor (e.g., BBP-398) | Advanced Solid Tumors (e.g., NSCLC with KRAS mutations) | Phase 1/2 |
| SHP2 Inhibitor + KRAS G12C Inhibitor Combination | KRAS G12C-mutant Solid Tumors | Phase 1/2 |